Delving into the Latest Updates on Beijing Nuoning Biotechnology Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Digestive System Disorders

Neoplasms

Genetically engineered subunit vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	1
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Genetically engineered subunit vaccine	1

[Translation] A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the protective efficacy, safety and immunogenicity of a recombinant 14-valent human papillomavirus (HPV) vaccine (types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) (insect cells) in healthy females aged 18 to 45 years

与安慰剂比较，评价接种3剂HPV疫苗（SCT1000）在18-45周岁健康女性中预防HPV6,11,16,18,31,33,35,39,45,51,52,56,58,59型别相关病变的保护效力。

[Translation]

To evaluate the protective efficacy of three doses of HPV vaccine (SCT1000) compared with placebo in preventing HPV6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59-related lesions in healthy women aged 18-45 years.

Start Date31 Aug 2023

Sponsor / Collaborator

Beijing Nuoning Biotechnology Co., Ltd.

[+1]

CTR20212245 / CompletedPhase 2

随机、双盲、阳性及安慰剂对照评价重组十四价人乳头瘤病毒疫苗（6,11,16,18,31,33,35,39,45,51,52,56,58,59型）（昆虫细胞）在18-45周岁健康女性人群中免疫原性和安全性的Ⅱ期临床试验

[Translation] A randomized, double-blind, positive and placebo-controlled phase II clinical trial to evaluate the immunogenicity and safety of recombinant 14-valent human papillomavirus vaccine (types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) (insect cells) in healthy females aged 18-45 years

评价SCT1000在18-45周岁健康女性人群中的免疫原性、安全性

[Translation]

To evaluate the immunogenicity and safety of SCT1000 in healthy females aged 18-45 years

Start Date19 Oct 2021

Sponsor / Collaborator

Beijing Nuoning Biotechnology Co., Ltd.

[+1]

CTR20211222 / CompletedPhase 1

随机、双盲、阳性及安慰剂对照、剂量递增评价重组十四价人乳头瘤病毒疫苗（6,11,16,18,31,33,35,39,45,51,52,56,58,59型）（昆虫细胞）在18-45周岁健康女性人群中安全性和耐受性的Ⅰ期临床试验

[Translation] A randomized, double-blind, positive and placebo-controlled, dose-escalation phase I clinical trial to evaluate the safety and tolerability of a recombinant 14-valent human papillomavirus vaccine (types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) (insect cells) in healthy females aged 18-45 years

评价SCT1000在18-45周岁健康女性人群中的安全性和耐受性。

[Translation]

To evaluate the safety and tolerability of SCT1000 in healthy females aged 18-45 years.

Start Date01 Jul 2021

Sponsor / Collaborator

Beijing Nuoning Biotechnology Co., Ltd.

[+1]

100 Clinical Results associated with Beijing Nuoning Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Nuoning Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Beijing Nuoning Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Nuoning Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data